ABSTRACT
Objective To investigate the suppressive effects of Maytansine on the proliferation,migration and invasion of nasopharyngeal carcinoma (NPC) cells.Methods MTT assay was employed to study the effect of Maytansine on the viability of 5-8F and SUNE1 cell lines.Wound healing assays and transwell were used to assess the effects of Maytansine on the migration and invasion capacities of NPC cells.Furthermore,an integrated bioinformatics analysis was conducted to clarify the potential mechanisms of Maytansine.Results Time course analysis of Maytansine treated NPC cells indicated significant decrease in cell viability,assessed by MTT.Furthermore,we identified that Maytansine reduced the migration and invasion capacities of NPC cells.Moreover,bioinformatics analysis showed that Maytansine suppressed the proliferation,migration and invasion via the upregulation of CDKN1B,BMP2,HBEGF,SMAD6,ADM,VEGFA,CTGF and IL6 in NPC cells.Conclusion Maytansine plays a significant suppressive role in the proliferation,migration and invasion of NPC cells and may be explored further for its potential therapeutic effects on NPC in humans.
ABSTRACT
Compared with the traditional anti-tumor therapy,the antibody-based therapeutic strategies have shown consider?ably higher targeting selectivity and lower side effects. Antibody drug conjugates(ADC),combining the advantage of the biological antibodies and small molecule toxins,is regarded as a new way for the future cancer therapy. Maytansines are one of the cytotoxins widely used in ADC and the postmarketing ADC ado-trastuzumab emtansine(Kadcyla,ATE)which use such toxins successfully has expanded the indications from leukemia to other solid tumors. Currently,the clinical research progress in such ADC goes smoothly. This paper reviews the characteristics,metabolic characteristics,preparation of each component and the latest clinical research prog?ress in the maytansine class ADC.
ABSTRACT
Compared with the traditional anti-tumor therapy, the antibody-based therapeutic strategies have shown considerably higher targeting selectivity and lower side effects. Antibody drug conjugates (ADC), combining the advantage of the biological antibodies and small molecule toxins, is regarded as a new way for the future cancer therapy. Maytansines are one of the cytotoxins widely used in ADC and the postmarketing ADC ado-trastuzumab emtansine (Kadcyla, ATE) which use such toxins successfully has expanded the indications from leukemia to other solid tumors. Currently, the clinical research progress in such ADC goes smoothly. This paper reviews the characteristics, metabolic characteristics, preparation of each component and the latest clinical research progress in the maytansine class ADC.